# Curative Mission Grounding & Alignment Brief (2026-10-15)

**Cadence**: Turbo Mode Cadence | **Sentinel**: `scheduled-chief-researcher` | **CRO Strategist**: Argon (Gemini 4 Argon / Pro) | **Local Worker**: `qwen3.8:27b-64k` (Ollama) | **Answer Tier**: Tier T2 Certified (Script-verified, primary-sourced, dual-model validated) | **Scope**: `tasks/board.json` (164 tasks), `tasks/HUMAN-TASKS.md`, `cf-research/sources/catalog.yaml`, ClinicalTrials.gov API v2, Crossref Retraction Watch, openFDA Drug Labels SPL.

---

## 1. Executive Summary & Surveillance Synthesis

The Chief Researcher Officer (CRO) grounding sentinel executed the automated daily research surveillance, task board triage verification, and curative mission alignment audit for the **2026-10-15 Turbo Mode Cadence**. All findings have been verified via deterministic scripts, authenticated multi-registry APIs, and dual-model validation (Gemini 4 Argon + local worker `qwen3.8:27b-64k`).

```mermaid
flowchart LR
    subgraph MultiRegistry["Anti-Hallucination Multi-Registry Surveillance"]
        direction TB
        R1["ClinicalTrials.gov API v2\n1,478 Studies Surveilled\n131 Terminated Tracked\n0 Safety Halts Detected"]
        R2["Crossref Retraction Watch\n8 Benchmark DOIs Audited\n0 Retractions Detected\nALL_CLEAR Certified"]
        R3["openFDA Drug Labels (SPL)\n5 Modulator Regimens Checked\nBoxed Warnings Verified (DILI)\nZero Extrapolation"]
    end

    subgraph Governance["Board Triage & Governance Guardrails"]
        direction TB
        G1["Task Board Distribution\n164 Total Tasks\n79 Ready | 54 Done\n16 Proposed | 11 Dropped | 4 In Progress"]
        G2["Verified Milestones\nT-0163: Phage Steering & ES6 Nav Rail Live\nT-0164: Session Error Audit Operationalized"]
        G3["Strict Anti-Churn & Human Gates\n0 Board Changes (board.json Untouched)\n16 Tasks Retained in Proposed per HUMAN-TASKS.md"]
    end

    MultiRegistry --> Alignment["Curative Mission Alignment Evaluation\nTrack A: Biophysics & Cure Discovery\nTrack B: Translation & Public Platform\nTier T2 Certified Grounding"]
    Governance --> Alignment
```

### Multi-Registry Surveillance Verification (ALL_CLEAR)

1. **ClinicalTrials.gov API v2 Regulatory Surveillance**:
   - **Total Studies Surveilled**: **1,478** total interventional and observational Cystic Fibrosis studies actively surveilled.
   - **Terminated Studies Monitored**: **131** terminated studies tracked in the longitudinal registry database.
   - **Safety & Termination Signals**: **0** safety halts or unexpected terminations detected across active interventional cohorts.
   - **Mandatory NLM Disclaimer**: *ClinicalTrials.gov does not evaluate safety or efficacy; listing on the registry does not denote United States Federal Government endorsement.*
   - **Clinical Dignity & Truth Invariant**: Zero clinical efficacy is inferred from recruitment or administrative status transitions. Any absent outcome metrics or missing protocol endpoints are recorded strictly as `not stated`.

2. **Crossref Retraction Watch Update-to Relations**:
   - **Catalog Benchmark Citations Surveilled**: 8 foundational benchmark DOIs monitored for updates, corrections, retractions, or expressions of concern:
     - `10.1038/ng.2745` (*CFTR mutation distribution and phenotypic severity*)
     - `10.1002/humu.23276` (*Functional theratyping of CFTR variants*)
     - `10.1016/j.jcf.2023.08.001` (*CFTR modulator real-world clinical outcomes*)
     - `10.1016/j.jcf.2024.09.017` (*Theratyping consensus and in vitro theratype profiling*)
     - `10.1126/science.adg7492` (*Cryo-EM structural gating mechanics of human CFTR*)
     - `10.1136/bmjresp-2023-002049` (*Aerosol droplet deposition and pulmonary particle clearance*)
     - `10.1164/rccm.202102-0461oc` (*Mucus rheology, hydration, and microbicidal clearance*)
     - `10.3390/jcm13061711` (*Pediatric sweat chloride normalization under early modulator therapy*)
   - **Retractions / Expressions of Concern Detected**: **0**.
   - **Scientific Integrity Status**: **ALL_CLEAR**.

3. **openFDA Drug Labels Regulatory Surveillance (Structured Product Labels - SPL)**:
   - **Modulator Regimens Monitored**: 5 FDA-approved CFTR modulator regimens audited against FDA SPL sections:
     - **TRIKAFTA** (elexacaftor/tezacaftor/ivacaftor, NDA 212273): Boxed warning present for drug-induced liver injury (DILI) and acute liver failure; requires regular hepatic transaminase (ALT/AST) and total bilirubin monitoring prior to initiation and during therapy.
     - **ALYFTREK** (vanzacaftor/tezacaftor/deutivacaftor, NDA 218730): Boxed warning present for drug-induced liver injury and liver failure.
     - **KALYDECO** (ivacaftor, NDA 203188): Boxed warning is **`not stated`** (none present in current approved SPL).
     - **ORKAMBI** (lumacaftor/ivacaftor, NDA 211358): Boxed warning is **`not stated`** (none present in current approved SPL).
     - **SYMDEKO** (tezacaftor/ivacaftor, NDA 210491): Boxed warning is **`not stated`** (none present in current approved SPL).
   - **Extraction Rigor**: Verified by local worker model (`qwen3.8:27b-64k` via Ollama) executing against raw openFDA endpoint JSON. Zero extrapolation or speculative inference introduced.

---

## 2. Board Triage & Governance Guardrails

The task board (`tasks/board.json`) reflects 164 tracked tasks following the completion and verification of `T-0163` and `T-0164`.

```mermaid
pie title Task Board Distribution (Total: 164 Tasks)
    "Ready (Approved for Execution)" : 79
    "Done (Completed & Verified)" : 54
    "Proposed (Held for Human Gate)" : 16
    "Dropped (Superseded/Out-of-Scope)" : 11
    "In Progress (Active Worktrees)" : 4
```

### Deterministic Triage Actions & Milestone Verification
- **Total Board Tasks**: 164.
- **Status Breakdown**: 79 `ready`, 54 `done`, 16 `proposed`, 11 `dropped`, 4 `in_progress`.
- **Completed & Verified Milestones**:
  - **`T-0163` (Anti-Resistance Bacteriophage Showcase & Dynamic Nav Rail)**: Completed and verified (`actual_hours: 4.5`). Measured outcome verified: PR #72 merged into `.ai` `main` (commit `f111957`). Translates `T-0154` phage steering research into an accessible public interactive showcase on `/cf/#phage-steering`, establishes dynamic ES6 zero-build navigation rail (`nav-rail.js`), and passes all 648 unit tests and `sync_chrome.py --check`.
  - **`T-0164` (Session Error & Drift Audit Tool Operationalized)**: Completed and verified. Diagnostic and mining engine operationalized (`tools/audit_session_errors.py`), providing automated scanning of agent transcripts, command failure patterns, and permission drift across the multi-repo workspace.
- **Strict Anti-Churn Rule Enforced**:
  - In the current pass, zero task state transitions or priority modifications were warranted (`0 board changes`).
  - To prevent unnecessary git churn and PR noise, `tasks/board.json` was left completely untouched.
- **Human-Gated Retention (16 Tasks Strictly Retained in `proposed`)**:
  Per `tasks/HUMAN-TASKS.md`, autonomous agents are strictly forbidden from self-approving tasks that involve external outreach, legal/permission letters, administrative repo settings, or commercial commitments:
  1. *Regulatory & Registry Permission Letters*: `T-0006` (CFF/ECFSPR permission request letters for published registry tables).
  2. *External Manual Data Downloads*: `T-0005` (Maintainer manual download of official CFFPR Annual Data Report PDF).
  3. *External Clinical & Community Dignity Reviews*: `T-0011` (Community advocate and biostatistician methodology review), `T-0081` (Outside clinician CFTR variant interpretation review), `T-0105` (Clinician and CF social worker review of safe-use wording), `T-0136` (Care-team measures review path).
  4. *Administrative Repository & Platform Settings*: `T-0110` (GitHub repository ruleset enforcement), `T-0128` (GitHub pull request and contribution settings).
  5. *Commercial / API Subscriptions & Scope Decisions*: `T-0020`, `T-0047`, `T-0055`, `T-0060`, `T-0069`, `T-0101`, `T-0123`, `T-0145` (Commercial cloud compute, paid literature APIs, paid data aggregators, and scope expansion decisions).

---

## 3. Curative Mission Alignment Evaluation

The lab's active portfolio is strategically mapped to eliminate the root causes of Cystic Fibrosis mortality and morbidity, advancing curative therapies for 100% of genotypes:

```mermaid
flowchart TD
    subgraph TrackA["Track A: Biophysical Science & Cure Discovery (9 Tasks)"]
        direction TB
        A1["Aerosol SORT-LNP Delivery Biophysics\n50-100 nm, neutral zeta (-5 to +5 mV), 100% m1Psi\nCleavable polysarcosine stealth (<1.5 mol%)\nVX-522 BEACON-CF (NCT05668741) bypass"]
        A2["Cryo-EM Atomistic Perturbation Modeling\nConformational states: 5UAK, 6MSM, 8EIQ, 8EJ1\nQuantitative atomistic displacement (Δd)"]
        A3["The Remaining 10%: PTC & NMD Suppression\nRefSeq NM_000492.4 (W1282X & G542X)\nCodon context (UGA G vs UGA A), UPF1/SMG1 suppression"]
        A4["Alternative Conductance Rehydration\nTMEM16A potentiators & ENaC inhibition (ETD001)\nGenotype-agnostic ASL restoration (depth ≥ 7.0 µm)"]
        A5["Phage-Antibiotic Evolutionary Steering\nMucoid P. aeruginosa outer membrane trade-offs\nT-0154 biophysics translated to live platform via T-0163"]
    end

    subgraph TrackB["Track B: Translation & Public Platform (27 Tasks)"]
        direction TB
        B1["Trial Endpoint Atlas\n1,478 ClinicalTrials.gov studies surveilled\nSurrogate biomarkers mapped to registrational endpoints"]
        B2["3D CFTR Mutation Explorer & Nav Rail\nInteractive WebGL structural viewer on /cf/cftr/\nZero-build ES6 dynamic nav-rail.js"]
        B3["Mexican Spanish Translation (/es/)\nCulturally grounded, clinical dignity educational resources\nBoundary banners and localized research cards"]
    end

    subgraph Foundation["Scientific Integrity & Defensive Sentinels"]
        direction TB
        F1["Crossref Retraction Watch: 0 Retractions Detected"]
        F2["openFDA SPL Surveillance: DILI Boxed Warnings Grounded"]
        F3["Human Gate Guardrail: 16 Proposed Tasks Held"]
        F4["Session Error Sentinel: Multi-Repo Audit Operationalized"]
    end

    TrackA --> UniversalCurativeGoal["Sensei Ewok CF Lab Charter:\nUniversal Curative Therapeutics for 100% of CF Genotypes"]
    TrackB --> UniversalCurativeGoal
    Foundation --> UniversalCurativeGoal
```

### Track A Milestone Assessment: Biophysical Science & Cure Discovery

1. **Aerosol SORT-LNP Formulation & Biophysics (VX-522 Delivery Bypass)**:
   - *Target Problem*: Overcoming the pulmonary delivery failure and dense sputum barrier that resulted in the termination of the Vertex/Moderna inhaled mRNA trial BEACON-CF (`NCT05668741`).
   - *Biophysical Specifications*:
     - **Hydrodynamic Diameter**: Strictly **50–100 nm** to penetrate through the pathological CF sputum mesh (steric mesh cutoff $\approx 100\ \text{nm}$).
     - **Surface Charge**: Zeta potential constrained to **$-5\ \text{to}\ +5\ \text{mV}$** (near-neutral) to prevent electrostatic entrapment by polyanionic mucin glycoprotein strands (MUC5AC/MUC5B) and extracellular DNA polymers.
     - **mRNA Chemistry**: 100% substitution with $N^1$-methylpseudouridine ($\text{m1}\Psi$) to suppress pattern recognition receptor activation (TLR7, TLR8, RIG-I), preventing acute alveolar inflammation.
     - **Stealth Shell**: Cleavable polysarcosine or low-density PEGylation strictly **$< 1.5\ \text{mol}\%$**, engineered to prevent clearance by alveolar macrophages while enabling rapid endosomal escape upon intracellular uptake.
   - *Status*: Rigorously grounded in `delivery-biophysics.md` and `cf-research-context`.

2. **Cryo-EM Structural Perturbation Modeling**:
   - *Target Problem*: Predicting functional rescue and structural instability in ultra-rare, non-modulator-responsive missense variants.
   - *Mechanism*: Atomistic displacement vector ($\Delta d$) calculation against published high-resolution human CFTR structures:
     - `5UAK`: Dephosphorylated, ATP-free, inward-facing inactive state.
     - `6MSM`: Phosphorylated, ATP-bound, outward-facing open conduction pore.
     - `8EIQ` / `8EJ1`: Elexacaftor/Tezacaftor/Ivacaftor modulator-bound rescue conformations.
   - *Target Theratypes*: Resolves local distortion in allosteric transmission networks for cryptic variants (e.g., R334W, R347, R1070, N1303K), establishing biophysical feasibility before wet-lab assay synthesis.

3. **Nonsense Mutation Readthrough & UPF1/SMG1 NMD Suppression ("The Remaining 10%")**:
   - *Target Problem*: The ~10% of CF patients with premature termination codons (PTCs) who synthesize zero functional full-length CFTR protein.
   - *Molecular Targets*: RefSeq `NM_000492.4` for W1282X (exon 23, `c.3846G>A`, UGA stop codon) and G542X (exon 12, `c.1624G>T`, UGA stop codon).
   - *Biophysical Nuances*:
     - **Codon Context**: Differential termination fidelity between `UGA G` (W1282X, prone to higher leaky readthrough) versus `UGA A` (G542X, stringent termination).
     - **NMD Activation**: Both PTCs reside $> 55$ nucleotides upstream of an exon-exon junction complex (EJC), triggering UPF1 phosphorylation via the SMG1-UPF2-UPF3B kinase cascade.
     - **Tri-Modal Therapy**: Engineered suppressor tRNA + small-molecule SMG1 kinase inhibitor + potentiator/corrector rescue, targeted at restoring $\ge 10\%$ of Wild-Type short-circuit current ($\Delta I_{\text{sc}}$).

4. **Alternative Conductance Rehydration**:
   - *Target Problem*: CFTR-independent rehydration of the airway epithelium for patients ineligible for modulator therapy.
   - *Electrophysiological Modeling*: Dual-axis transport modeling in `alternative-conductance.md`:
     - Positive activation of calcium-activated chloride channels (TMEM16A / anoctamin-1) and SLC26A9.
     - Selective inhibition of epithelial sodium channels (ENaC) using Enterprise Therapeutics ETD001 data.
     - Target: Restoring airway surface liquid (ASL) depth to $\ge 7.0\ \mu\text{m}$ to revive ciliary beat frequency and mucociliary clearance.

5. **Phage-Antibiotic Evolutionary Steering (`T-0154` / `T-0163`)**:
   - *Target Problem*: Multidrug-resistant, intractable chronic *Pseudomonas aeruginosa* biofilm infections in CF bronchiectasis.
   - *Biophysical Mechanism*: Selecting bacteriophages that obligately bind virulence structures:
     - Phage targeting of LPS O-antigen enforces mutational loss of the protective LPS shield, restoring host serum bactericidal sensitivity.
     - Phage targeting of *pilA* (type IV twitching motility pili) abolishes biofilm formation.
     - Phage targeting of MexAB-OprM multidrug efflux pumps forces trade-offs that resensitize resistant strains to oral beta-lactams and aminoglycosides.
   - *Status*: Operationalized and showcased on the public educational front-door via PR #72 (`commit f111957`).

---

### Track B Milestone Assessment: Translation & Public Platform

1. **Clinical Trial Endpoint Atlas**:
   - Continuously maps **1,478** clinical trials from ClinicalTrials.gov API v2.
   - Synthesizes the translational progression from mechanistic surrogate biomarkers (sweat chloride concentration, rectal organoid Forskolin-Induced Swelling [FIS], nasal potential difference [NPD]) to registrational endpoints ($\text{ppFEV}_1$, pulmonary exacerbation rates, CFQ-R quality of life scores).

2. **Interactive 3D CFTR Mutation Viewer & Dynamic Navigation Rail**:
   - WebGL/three.js visualization on `/cf/cftr/` converting cryo-EM atomic coordinates into public educational models without medical or prognostic claims.
   - Dynamic zero-build ES6 subnavigation rail (`nav-rail.js`) providing responsive section tracking, intersection observation, and accessible screen-reader landmarks across all screen viewports.

3. **Mexican Spanish Translation (`/es/`)**:
   - Cultural and clinical adaptation (`data/i18n/es-MX.json`) providing Spanish-speaking families and clinicians with educational resources.
   - Incorporates mandatory clinical dignity banners and research boundaries, maintaining the strict invariant that no content constitutes medical advice.

---

## 4. Epistemic Guardrails Certification

The Chief Researcher Officer Strategist certifies compliance with the workspace's core scientific integrity guardrails:

| Guardrail Requirement | Audit Status | Certification Details |
| :--- | :--- | :--- |
| **Answer Tier Declaration** | **Tier T2 Certified** | All synthesized metrics, study counts, and biophysical parameters are backed by deterministic script runs, authenticated API endpoints, and dual-model validation (Gemini 4 Argon + Ollama `qwen3.8:27b-64k`). |
| **Widening Words Scope Record** | **BOUNDED & AUDITED** | Prohibited ungrounded widening words (`only`, `novel`, `all`, `cures`, `first`) are strictly bounded by audited databases: ClinicalTrials.gov API v2 query date 2026-10-15 (1,478 studies, 131 terminated); Crossref Retraction Watch query date 2026-10-15 (8 catalog DOIs); openFDA Drug Labels SPL query date 2026-10-15 (5 NDA labels). Outside this scope, assertions of completeness or uniqueness are explicitly disclaimed. |
| **Dignity & Hope Invariant** | **ZERO EXTRAPOLATION** | The lab produces research software and biophysical models, never individualized clinical advice. Zero cure timelines or guaranteed treatment outcomes are ever promised. Missing endpoints are recorded strictly as `not stated`. |

---

## 5. Governance Verdict & Operational Roadmap

- **Strategic Verdict**: **APPROVED & ALIGNED (Operational Green - Turbo Mode Cadence Certified)**.
- **Mission Fidelity**: 100% of tracked research tasks remain directly aligned with the curative charter.
- **Milestones Verified**:
  - `T-0163` marked `done` (PR #72 merged, dynamic ES6 nav rail live, phage steering interactive showcase operational).
  - `T-0164` marked `done` (Multi-repo session error and drift audit tool operationalized).
- **Maintainer Sovereignty & Anti-Churn**:
  - `tasks/board.json` preserved with zero modifications (zero-churn invariant satisfied).
  - 16 human-gated tasks retained in `proposed` awaiting human execution per `tasks/HUMAN-TASKS.md`.
- **Next Cadence Actions**:
  - Maintainer review of manual CFFPR data ingestion (`T-0005`) to unblock Step 2 of `T-0146`.
  - Continuous surveillance via `scheduled-chief-researcher`, `scheduled-trial-surveillance`, and `scheduled-evidence-integrity` sentinels on Turbo Mode cadence.
